CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-15 | Gayer Charles K Vice President and CCO | Grant or award · Emp. Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2020-12-15 | Barnes Alane P Senior VP, Chief Legal Officer | Grant or award · Emp. Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2020-12-15 | Babu Yarlagadda S Senior VP - Drug Discovery | Grant or award · Emp. Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2020-12-15 | Sheridan William P Senior VP - CMO | Grant or award · Emp. Stock Option (Right to Buy) | +335,000 | 335,000 | ||
| 2020-12-15 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +332,500 | 332,500 | ||
| 2020-12-15 | Stonehouse Jon P President & CEO | Option exercise | +134,278 | $4.15 | $557K | 918,364 |
| 2020-12-15 | Stonehouse Jon P President & CEO | Sale | −134,278 | $8.32 | $1.1M | 784,086 |
| 2020-12-15 | Stonehouse Jon P President & CEO | Option exercise · Emp. Stock Option (Right to Buy) | −134,278 | 1 | ||
| 2020-12-15 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +870,000 | 870,000 | ||
| 2020-12-11 | Barnes Alane P Senior VP, Chief Legal Officer | Option exercise | +13,741 | $4.15 | $57K | 121,802 |
| 2020-12-11 | Barnes Alane P Senior VP, Chief Legal Officer | Sale | −13,741 | $7.96 | $109K | 108,061 |
| 2020-12-11 | Barnes Alane P Senior VP, Chief Legal Officer | Option exercise · Emp. Stock Option (Right to Buy) | −13,741 | 0 | ||
| 2020-12-04 | Barnes Alane P Senior VP, Chief Legal Officer | Option exercise | +13,741 | $4.15 | $57K | 121,802 |
| 2020-12-04 | Barnes Alane P Senior VP, Chief Legal Officer | Sale | −13,741 | $6.23 | $86K | 108,061 |
| 2020-12-04 | Barnes Alane P Senior VP, Chief Legal Officer | Option exercise · Emp. Stock Option (Right to Buy) | −13,741 | 13,741 | ||
| 2020-12-03 | Jones Michael L Exec. Director, Finance - PAO | Grant or award · Emp. Stock Option (Right to Buy) | +5,000 | 5,000 | ||
| 2020-12-03 | Sheridan William P Senior VP - CMO | Grant or award · Emp. Stock Option (Right to Buy) | +17,000 | 17,000 | ||
| 2020-12-03 | Barnes Alane P Senior VP, Chief Legal Officer | Grant or award · Emp. Stock Option (Right to Buy) | +17,000 | 17,000 | ||
| 2020-12-03 | Babu Yarlagadda S Senior VP - Drug Discovery | Grant or award · Emp. Stock Option (Right to Buy) | +17,000 | 17,000 | ||
| 2020-12-03 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +25,000 | 25,000 |
Page 24 of 27 · 522 trades